Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BDNF Release Is Required for the Behavioral Actions of Ketamine
Ashley E. Lepack, Manabu Fuchikami, J. M. Dwyer, et al.
The International Journal of Neuropsychopharmacology (2014) Vol. 18, Iss. 1, pp. pyu033-pyu033
Open Access | Times Cited: 343

Showing 26-50 of 343 citing articles:

The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders
Yang Jin, Li Sun, Wei Yang, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 168
Ketamine: A tale of two enantiomers
Luke A. Jelen, Allan H. Young, James Stone
Journal of Psychopharmacology (2020) Vol. 35, Iss. 2, pp. 109-123
Open Access | Times Cited: 164
The physiology of regulated BDNF release
Tanja Brigadski, Volkmar Leßmann
Cell and Tissue Research (2020) Vol. 382, Iss. 1, pp. 15-45
Open Access | Times Cited: 150
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Satoshi Deyama, Ronald S. Duman
Pharmacology Biochemistry and Behavior (2019) Vol. 188, pp. 172837-172837
Open Access | Times Cited: 149
Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial
Raíssa Nóbrega de Almeida, Ana Cecília de Menezes Galvão, Flávia Santos da Silva, et al.
Frontiers in Psychology (2019) Vol. 10
Open Access | Times Cited: 145
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?
Beatrice Arosio, Franca Rosa Guerini, Richard C. Oude Voshaar, et al.
Frontiers in Behavioral Neuroscience (2021) Vol. 15
Open Access | Times Cited: 111
Ketamine: Mechanisms and Relevance to Treatment of Depression
Ji‐Woon Kim, Kanzo Suzuki, Ege T. Kavalali, et al.
Annual Review of Medicine (2023) Vol. 75, Iss. 1, pp. 129-143
Closed Access | Times Cited: 51
Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression
Ji‐chun Zhang, Wei Yao, Chao Dong, et al.
Psychopharmacology (2015) Vol. 232, Iss. 23, pp. 4325-4335
Closed Access | Times Cited: 166
Identifying fast-onset antidepressants using rodent models
Marcia J. Ramaker, Stephanie C. Dulawa
Molecular Psychiatry (2017) Vol. 22, Iss. 5, pp. 656-665
Open Access | Times Cited: 163
Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures
Ashley E. Lepack, Eunyoung Bang, Boyoung Lee, et al.
Neuropharmacology (2016) Vol. 111, pp. 242-252
Open Access | Times Cited: 162
Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine
Kenichi Fukumoto, Manoela V. Fogaça, Rong-Jian Liu, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 116, Iss. 1, pp. 297-302
Open Access | Times Cited: 161
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
Domenico De Berardis, Michele Fornaro, Alessandro Valchera, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 10, pp. 2888-2888
Open Access | Times Cited: 159
Convergent Mechanisms Underlying Rapid Antidepressant Action
Panos Zanos, Scott M. Thompson, Ronald S. Duman, et al.
CNS Drugs (2018) Vol. 32, Iss. 3, pp. 197-227
Open Access | Times Cited: 154
Rett Syndrome: Crossing the Threshold to Clinical Translation
David M. Katz, Adrian Bird, Monica Coenraads, et al.
Trends in Neurosciences (2016) Vol. 39, Iss. 2, pp. 100-113
Open Access | Times Cited: 146
Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Bashkim Kadriu, Laura Musazzi, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 22, Iss. 2, pp. 119-135
Open Access | Times Cited: 144
Neuronal correlates of depression
Dipesh Chaudhury, He Liu, Ming‐Hu Han
Cellular and Molecular Life Sciences (2015) Vol. 72, Iss. 24, pp. 4825-4848
Open Access | Times Cited: 134
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Esa R. Korpi, Bjørnar den Hollander, Usman Farooq, et al.
Pharmacological Reviews (2015) Vol. 67, Iss. 4, pp. 872-1004
Open Access | Times Cited: 133
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Eric S. Wohleb, Danielle M. Gerhard, Alex Thomas, et al.
Current Neuropharmacology (2016) Vol. 15, Iss. 1, pp. 11-20
Open Access | Times Cited: 132
Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling
Laura Cavalleri, Emilio Merlo Pich, Mark J. Millan, et al.
Molecular Psychiatry (2017) Vol. 23, Iss. 4, pp. 812-823
Open Access | Times Cited: 130
Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Ronald S. Duman, Ryota Shinohara, Manoela V. Fogaça, et al.
Molecular Psychiatry (2019) Vol. 24, Iss. 12, pp. 1816-1832
Open Access | Times Cited: 129
Ketamine for the treatment of addiction: Evidence and potential mechanisms
Ivan Ezquerra-Romano, Will Lawn, Evgeny Krupitsky, et al.
Neuropharmacology (2018) Vol. 142, pp. 72-82
Open Access | Times Cited: 128
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Panos Zanos, Jaclyn N. Highland, Brent W. Stewart, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 13, pp. 6441-6450
Open Access | Times Cited: 128
Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT
Andrew P. Allen, M. Naughton, Joshua L. Dowling, et al.
Journal of Affective Disorders (2015) Vol. 186, pp. 306-311
Closed Access | Times Cited: 125
A hypothesis of monoamine (5-HT) – Glutamate/GABA long neural circuit: Aiming for fast-onset antidepressant discovery
Yunfeng Li
Pharmacology & Therapeutics (2020) Vol. 208, pp. 107494-107494
Closed Access | Times Cited: 123

Scroll to top